Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Cboe UK CHF

Novartis AG (NOVNZ.XC)

Compare
101.58
+0.56
+(0.55%)
At close: March 10 at 4:19:59 PM GMT
Loading Chart for NOVNZ.XC
  • Previous Close 101.02
  • Open 101.16
  • Bid 101.58 x --
  • Ask 101.58 x --
  • Day's Range 100.38 - 101.84
  • 52 Week Range 83.65 - 102.72
  • Volume 913,877
  • Avg. Volume 698,798
  • Market Cap (intraday) 200.63B
  • Beta (5Y Monthly) 0.49
  • PE Ratio (TTM) 19.72
  • EPS (TTM) 5.15
  • Earnings Date Apr 29, 2025
  • Forward Dividend & Yield 3.50 (3.45%)
  • Ex-Dividend Date Mar 11, 2025
  • 1y Target Est --

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

www.novartis.com

75,883

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NOVNZ.XC

View More

Performance Overview: NOVNZ.XC

Trailing total returns as of 3/10/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD .

YTD Return

NOVNZ.XC
18.73%
MSCI WORLD
1.88%

1-Year Return

NOVNZ.XC
19.51%
MSCI WORLD
7.95%

3-Year Return

NOVNZ.XC
26.71%
MSCI WORLD
26.62%

5-Year Return

NOVNZ.XC
26.71%
MSCI WORLD
82.89%

Compare To: NOVNZ.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NOVNZ.XC

View More

Valuation Measures

Annual
As of 3/10/2025
  • Market Cap

    200.23B

  • Enterprise Value

    215.95B

  • Trailing P/E

    19.72

  • Forward P/E

    14.16

  • PEG Ratio (5yr expected)

    3.46

  • Price/Sales (ttm)

    4.55

  • Price/Book (mrq)

    5.19

  • Enterprise Value/Revenue

    4.76

  • Enterprise Value/EBITDA

    11.88

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    23.09%

  • Return on Assets (ttm)

    10.09%

  • Return on Equity (ttm)

    26.27%

  • Revenue (ttm)

    51.72B

  • Net Income Avi to Common (ttm)

    11.94B

  • Diluted EPS (ttm)

    5.15

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.35B

  • Total Debt/Equity (mrq)

    71.16%

  • Levered Free Cash Flow (ttm)

    12.04B

Research Analysis: NOVNZ.XC

View More

Company Insights: NOVNZ.XC

Research Reports: NOVNZ.XC

View More

People Also Watch